LIVINGSTONE HEALTH HOLDINGS LIMITED

(Incorporated in the Republic of Singapore)
(Company Registration Number 200404283C)

MINUTES OF THE ANNUAL GENERAL MEETING
OF THE COMPANY HELD ON 28 JULY 2026

The Board of Directors ("**Board**") of Livingstone Health Holdings Limited (the "**Company**" and together with its subsidiaries, the "**Group**") refers to the Annual General Meeting of the Company held on Tuesday, 28 July 2026 ("**AGM**").

The Board would like to thank shareholders for their attendance at the AGM. Paragraph 6 of Practice Note 7E of the Catalist Rules requires the Company to release the minutes of AGM within one month after the date of AGM. The minutes of the AGM are set out at **Annex A**. The questions raised at the AGM and the Company's responses are set out in **Appendix A**.

BY ORDER OF THE BOARD

Dax Ng Yung Sern
Executive Director and Chief Commercial Officer
12 August 2026

---

*This announcement has been reviewed by the Company's sponsor, SAC Capital Private Limited (the "**Sponsor**"). This announcement has not been examined or approved by the Singapore Exchange Securities Trading Limited ("**SGX-ST**") and the SGX-ST assumes no responsibility for the contents of this announcement, including the correctness of any of the statements or opinions made or reports contained in this announcement.*

The contact person for the Sponsor is Ms Lee Khai Yinn (Telephone: (65) 6232 3210) at 1 Robinson Road, #21-01, AIA Tower, Singapore 048542.

ANNEX A

LIVINGSTONE HEALTH HOLDINGS LIMITED

(Incorporated in the Republic of Singapore)
(Company Registration Number 200404283C)
(the "**Company**")

MINUTES OF ANNUAL GENERAL MEETING

Date	:	Tuesday, 28 July 2026
Time	:	3.00 p.m.
Venue	:	Forvis Mazars Lounge, 135 Cecil Street, Level 7, Singapore 069536
Present	:	As set out in the attendance records maintained by the Company
Chairman	:	Mr Teh Wing Kwan

Introduction

Mr Teh Wing Kwan, the Non-Executive and Non-Independent Chairman of the Company, presided as Chairman of the Annual General Meeting (the "**AGM**" or "**Meeting**").

The Chairman welcomed the shareholders to the AGM.

The Chairman introduced the Board of Directors to the shareholders.

The Chairman conveyed the apologies of Dr Tay Ching Yit, Wilson, the Executive Director and Chief Executive Officer of the Company, who was unable to attend the Meeting.

Quorum

The Chairman stated that the Company Secretary has advised that a quorum was present and commenced with the business of the AGM.

Notice

The Chairman stated that the Annual Report for the financial year ended 31 March 2026 together with the Notice of AGM have been circulated to the shareholders via SGXNet announcement on 13 July 2026.

The Chairman suggested that the Notice of AGM be taken as read.

Questions from Shareholders

Shareholders have been given the opportunity to submit questions relating to the Ordinary Resolutions put to vote at the AGM by 5.00 p.m. on Monday, 20 July 2026. The Chairman noted that the Company had not received any questions from shareholders before the stated deadline.

The Chairman stated that shareholders will have the opportunity to ask questions during the course of the AGM.

The Company received questions from a shareholder during the course of the AGM. A summary of the questions raised by the shareholder at the AGM and the responses from the Company are annexed hereto and marked as **Appendix 1**.

Business Update and FY2026 Financial Overview

The Chairman started the meeting by sharing that during the year under review, the Group:

- streamlined its operations for improving operational efficiencies;
- closed its underperforming health screening centre to further rationalise its business;
- acquired another GP clinic to expand its primary care network; and
- took a 20% to 30% stake in specialist and general surgery clinics to further support its tertiary care.

The Chairman cautioned on the on-going inflationary pressures and rising business costs in a highly competitive operating environment for the healthcare industry.

The Chairman then invited the Management to present the business overview and financial performance of the Company before proceeding to the business of the AGM. Mr Wong Qingyuan, the Chief Financial Officer of the Company, presented on the business overview, corporate milestones and FY2026 financial highlights of the Company. Mr Dax Ng Yung Sern, the Executive Director and Chief Commercial Officer of the Company, then presented the business strategy and future plans of the Group. Dr Chua Hshan Cher, the Deputy Chief Executive Officer and Head of Family Medicine of the Company, then concluded with the aspirations and vision of the Group.

The corporate presentation slides that cover the Company's presentation have been published on SGXNet on 28 July 2026, under the general announcement titled "Corporate Presentation Deck for FY2026 AGM".

Voting

It was noted that the Ordinary Resolutions put to vote at the AGM would be decided on a poll.

As the Chairman had been appointed as proxy by some shareholders to vote in accordance with their instructions on their behalf prior to the AGM, the Ordinary Resolutions put to vote at the AGM were deemed to be proposed and seconded.

Boardroom Corporate & Advisory Services Pte. Ltd. was appointed as the Company's Polling Agent and Gong Corporate Services Pte. Ltd. was appointed as the Company's Scrutineers.

The Chairman invited a representative of the Company's Company Secretary to continue with the AGM proceedings on his behalf.

Ordinary Business

1. **Ordinary Resolution 1**

The Meeting was informed that Ordinary Resolution 1 was to receive and adopt the Directors' Statement and the Audited Financial Statements of the Company for the financial year ended 31 March 2026 together with the Auditors' Report thereon.

The motion had been put to vote by way of a poll.

The poll results were as follows:

	Number of shares	Percentage of total number of votes for and against (%)*
For	314,967,157	100.00
Against	3,360	0.00

** Percentages are rounded to two decimal places*

Based on the results of the poll, Ordinary Resolution 1 was declared duly carried by a majority vote and accordingly it was resolved:

"*That the Directors' Statement and the Audited Financial Statements of the Company for the financial year ended 31 March 2026 together with the Auditors' Report thereon be and are hereby received and adopted.*"

2. **Ordinary Resolution 2**

The Meeting was informed that Ordinary Resolution 2 was to approve the payment of Directors' fees of S$124,000 for the financial year ending 31 March 2027. (1 April 2025 to 31 March 2026: S$158,000).

The motion had been put to vote by way of a poll.

The poll results were as follows:

	Number of shares	Percentage of total number of votes for and against (%)*
For	314,965,357	100.00
Against	5,160	0.00

** Percentages are rounded to two decimal places*

Based on the results of the poll, Ordinary Resolution 2 was declared duly carried by a majority vote and accordingly it was resolved:

"*That the payment of a Directors' fees of S$124,000 for the financial year ending 31 March 2027, be and is hereby approved.*"

3. **Ordinary Resolution 3**

The Meeting was informed that Ordinary Resolution 3 was to re-appoint Forvis Mazars LLP as the Company's Auditors for the financial year ending 31 March 2027 and to authorise the Directors of the Company to fix their remuneration.

Forvis Mazars LLP had expressed their willingness to continue in office.

The motion had been put to vote by way of a poll.

The poll results were as follows:

	Number of shares	**Percentage of total number of votes for and against (%)***
For	314,967,157	100.00
Against	3,360	0.00

** Percentages are rounded to two decimal places*

Based on the results of the poll, Ordinary Resolution 3 was declared duly carried by a majority vote and accordingly it was resolved:

"*That Forvis Mazars LLP be re-appointed as the Company's Auditors for the financial year ending 31 March 2027 and the Directors of the Company be and are hereby authorised to fix their remuneration*."

4. **Ordinary Resolution 4**

The Meeting was informed that Ordinary Resolution 4 was to re-elect Mr Dax Ng Yung Sern, who is retiring pursuant to Regulation 104 of the Company's Constitution.

The Meeting noted that Mr Dax Ng Yung Sern will, upon re-election as a Director of the Company, remain as an Executive Director and Chief Commercial Officer of the Company.

The motion had been put to vote by way of a poll.

The poll results were as follows:

	Number of shares	**Percentage of total number of votes for and against (%)***
For	314,967,157	100.00
Against	3,360	0.00

** Percentages are rounded to two decimal places*

Based on the results of the poll, Ordinary Resolution 4 was declared duly carried by a majority vote and accordingly it was resolved:

"*That Mr Dax Ng Yung Sern, who is retiring pursuant to Regulation 104 of the Company's Constitution, be and is hereby re-elected as a Director of the Company*."

5. **Ordinary Resolution 5**

The Meeting was informed that Ordinary Resolution 5 was to re-elect Mr Fong Heng Boo, who is retiring pursuant to Regulation 104 of the Company's Constitution.

The Meeting noted that Mr Fong Heng Boo will, upon re-election as a Director of the Company, remain as the Lead Independent and Non-Executive Director, Chairman of the Audit Committee, and a member of the Nominating Committee and the Remuneration Committee of the Company. Mr Fong Heng Boo is considered independent for the purposes of Rule 704(7) of the Singapore Exchange Securities Trading Limited Listing Manual Section B: Rules of Catalist.

The motion had been put to vote by way of a poll.

The poll results were as follows:

	Number of shares	**Percentage of total number of votes for and against (%)***
For	314,967,137	100.00
Against	3,360	0.00

** Percentages are rounded to two decimal places*

Based on the results of the poll, Ordinary Resolution 5 was declared duly carried by a majority vote and accordingly it was resolved:

"*That Mr Fong Heng Boo, who is retiring pursuant to Regulation 104 of the Company's Constitution, be and is hereby re-elected as a Director of the Company*."

Special Business

6. Ordinary Resolution 6

The Meeting was informed that Ordinary Resolution 6 was to grant Directors of the Company authority to allot and issue shares in the capital of the Company.

The motion had been put to vote by way of a poll.

The poll results were as follows:

	Number of shares	**Percentage of total number of votes for and against (%)***
For	314,967,157	100.00
Against	3,360	0.00

** Percentages are rounded to two decimal places*

Based on the results of the poll, Ordinary Resolution 6 was declared duly carried by a majority vote and accordingly it was resolved:

"*That, pursuant to Section 161 of the Companies Act 1967 of Singapore (the "**Companies Act**") and Rule 806 of the Catalist Rules, authority be and is hereby given to the Directors of the Company to:*

*(a) (i) allot and issue new shares in the capital of the Company ("**Shares**") (whether by way of rights, bonus or otherwise); and/or*

*(ii) make or grant offers, agreements or options (collectively, "**Instruments**") that might or would require the Shares to be allotted and issued, including but not limited to the creation, allotment and issue of (as well as adjustments to) options, warrants, debentures or other instruments convertible into Shares,*

at any time and upon such terms and conditions and for such purposes and to such persons as the Directors of the Company may in their absolute discretion deem fit; and

(b) notwithstanding that the authority conferred by this Ordinary Resolution may have ceased to be in force, allot and issue Shares in pursuance of any Instrument made or granted by the Directors of the Company while this Ordinary Resolution is in force,

provided that:

(1) the aggregate number of new Shares (including Shares to be allotted and issued in pursuance of the Instruments made or granted pursuant to this Ordinary Resolution) to be allotted and issued pursuant to this Ordinary Resolution shall not exceed 100% of the total number of issued Shares (excluding treasury shares and subsidiary holdings) in the capital of the Company (as calculated in accordance with sub-paragraph (2) below), of which the aggregate number of new Shares to be allotted and issued other than on a pro rata basis to the members of the Company (including Shares to be allotted and issued in pursuance of Instruments made or granted pursuant to this Ordinary Resolution) does not exceed 50% of the total number of issued Shares (excluding treasury shares and subsidiary holdings) in the capital of the Company (calculated in accordance with sub-paragraph (2) below);

(2) subject to such calculation as may be prescribed by the SGX-ST, for the purpose of determining the aggregate number of new Shares that may be allotted and issued under sub-paragraph (1) above, the percentage total number of issued Shares (excluding treasury shares and subsidiary holdings) in the capital of the Company shall be based on the total number of issued Shares (excluding treasury shares and subsidiary holdings) in the capital of the Company at the time of the passing of this Ordinary Resolution, after adjusting for:

(i) new Shares arising from the conversion or exercise of any Instruments or any convertible securities;

(ii) new Shares arising from exercising of share options or vesting of share awards, provided that the share options or the share awards are granted in compliance with Part VIII of Chapter 8 of the Catalist Rules; and

(iii) any subsequent bonus issue, consolidation or sub-division of Shares;

Any adjustments made in accordance with sub-paragraphs 2(i) or (2)(ii) above shall only be made in respect of new Shares arising from convertible securities and Instruments which were issued and outstanding and/or subsisting at the time of passing this Ordinary Resolution;

(3) in exercising the authority conferred by this Ordinary Resolution, the Company shall comply with the provisions of the Catalist Rules for the time being in force (unless such compliance has been waived by the SGX-ST), the Companies Act and the Constitution of the Company for the time being; and

(4) unless revoked or varied by the Company in a general meeting, such authority conferred by this Ordinary Resolution shall continue in force until the conclusion of the next Annual General Meeting of the Company or the date by which the next Annual General Meeting of the Company is required by law to be held, whichever is the earlier."

7. **Ordinary Resolution 7**

The Meeting was informed that Ordinary Resolution 7 was to authorise the Directors to grant awards in accordance with the provisions of the LSHH PSP 2024 adopted on 31 July 2024 (the "**Performance Share Plan**") and to allot and issue shares in accordance with the Performance Share Plan.

The Meeting was informed that pursuant to Catalist Rule 858, all persons (including employees and Directors of the Company who are also Shareholders) who are eligible to participate in the Performance Share Plan must abstain from voting on all the resolutions relating to the Performance Share Plan at the Annual General Meeting (i.e. Ordinary Resolution 7 as set out in the Notice of AGM) and all persons (including those Directors who are also Shareholders) shall not accept nominations as proxies unless specific instructions have been given in the proxy instruments by the Shareholders appointing them on how they wish their votes to be cast.

The Meeting was further informed that the Company would disregard any votes cast on Ordinary Resolution 7 by all persons who are eligible to participate in the Performance Share Plan.

The motion had been put to vote by way of a poll.

The poll results were as follows:

	Number of shares	**Percentage of total number of votes for and against (%)***
For	14,896	81.60
Against	3,360	18.40

** Percentages are rounded to two decimal places*

Based on the results of the poll, Ordinary Resolution 7 was declared duly carried by a majority vote and accordingly it was resolved:

*"That the Directors of the Company be and are hereby authorised to grant awards (the "**Awards**") in accordance with the provisions of the LSHH PSP 2024 adopted on 31 July 2024 (the "**PSP**") and, subject to the provisions in the Companies Act and the Constitution of the Company, to allot and issue from time to time such number of fully paid-up Shares in the capital of the Company as may be required to be issued pursuant to the vesting of Awards provided that the aggregate number of Shares to be issued or issuable and/or transferred pursuant to the PSP and all options and awards granted under any other share-based incentive scheme(s) of the Company shall not exceed 15% of the issued Shares of the Company (excluding any Shares held in treasury and subsidiary holdings) from time to time."*

8. **Ordinary Resolution 8**

The Meeting was informed that Ordinary Resolution 8 was to authorise the Directors to grant awards in accordance with the provisions of the LSHH RSP 2024 adopted on 31 July 2024 (the "**Restricted Share Plan**") and to allot and issue shares in accordance with the Restricted Share Plan.

The Meeting was informed that pursuant to Catalist Rule 858, all persons (including employees and Directors of the Company who are also Shareholders) who are eligible to participate in the Restricted Share Plan must abstain from voting on all the resolutions relating to the Restricted Share Plan at the Annual General Meeting (i.e. Ordinary Resolution 8 as set out in the Notice of AGM) and all persons (including those Directors who are also Shareholders) shall not accept nominations as proxies unless specific instructions have been given in the proxy instruments by the Shareholders appointing them on how they wish their votes to be cast.

The Meeting was further informed that the Company would disregard any votes cast on Ordinary Resolution 8 by all persons who are eligible to participate in the Restricted Share Plan.

The motion had been put to vote by way of a poll.

The poll results were as follows:

	Number of shares	Percentage of total number of votes for and against (%)*
For	14,896	81.60
Against	3,360	18.40

** Percentages are rounded to two decimal places*

Based on the results of the poll, Ordinary Resolution 8 was declared duly carried by a majority vote and accordingly it was resolved:

*"That the Directors of the Company be and are hereby authorised to grant Awards in accordance with the provisions of the LSHH RSP 2024 adopted on 31 July 2024 (the "**RSP**") and, subject to the provisions of the Companies Act and the Constitution of the Company, to allot and issue from time to time such number of fully paid-up Shares in the capital of the Company as may be required to be issued pursuant to the vesting of Awards provided that the aggregate number of Shares to be issued or issuable and/or transferred pursuant to the RSP and all options and awards granted under any other share-based incentive scheme(s) of the Company shall not exceed 15% of the issued Shares of the Company (excluding any Shares held in treasury and subsidiary holdings) from time to time."*

<u>Conclusion</u>

The Chairman stated that the Company will publish the minutes of the AGM on the Company's website and SGXNet within a month after the AGM.

There being no other business, the Chairman declared the AGM closed and thanked all shareholders who attended the AGM.

Confirmed by
Teh Wing Kwan
Non-Executive and Non-Independent Chairman

Appendix 1

LIVINGSTONE HEALTH HOLDINGS LIMITED

(Incorporated in the Republic of Singapore)
(Company Registration Number 200404283C)
(the "**Company**")

QUESTIONS RAISED AT THE ANNUAL GENERAL MEETING OF THE COMPANY HELD ON 28 JULY 2026 AND THE COMPANY'S RESPONSES

Question 1

Shareholder A noted the Company's losses in FY2026 and asked how the Company can turn profitable in the future.

Response 1

Mr Dax Ng Yung Sern ("**Mr Ng**") informed that the Company's top line has seen approximately 6% year-on-year growth. Furthermore, if excluding Ardennes' losses and non-recurring expenses due to the closure of Ardennes, the Group would have achieved a higher net profit attributable to owners of the Company of approximately S$608,000 in FY2026 as compared to S$557,000 in FY2025. Mr Ng added that from a strategic business and operational point-of-view, and taking into account the headwinds faced by the Group's health screening centers, Management had made a strategic decision to close the unprofitable center down and redirect its resources with a view to improve financial performance.

Question 2

Shareholder A asked what the Company's unique strengths are, and how such strengths can allow the Company to remain competitive.

Response 2

Mr Ng responded that the Company's core strength is that it is led by a strategically-formed group of core doctors who have built the Company from the ground up, and hence, are able to better understand the pain points from both the doctor's and patient's perspectives.

Mr Ng informed that another core strength is that, as a growing small and medium enterprise ("**SME**"), the Company has flexibility in pursuing growth opportunities. That said, Mr Ng explained that the Company has been selective in evaluating acquisition plans, such that, being a patient care hub, it could vertically integrate targets and scale its operations.

Dr Chua Hshan Cher ("**Dr Chua**") added that, as a nimble SME, the Management is constantly on the lookout for physicians who mirror the Group's ethos in terms of primary care and specialist care, and that implementation of such growth initiatives would take time. That said, the Management will stay on the right track whilst growing its operations. To this end, Dr Chua explained that the Group would have to continuously bring in doctors who fit the Group's ethos and are already running clinics with track records, and at the same time, train the younger generation of physicians to be resident physicians in their clinics.

Dr Chua further explained that the Group's clinics are strategically spread across Singapore instead of being concentrated in one geographical area, as the Group believes this allows each clinic to serve and retain its patient base over the course of each physician's career.